xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

527

Orlandi et al.

A higher percentage of CD8 + T cells were present in AFRS/EMCRS.

(Continues)

common cell type in AFRS. CD20 + B cells were most

elevated in AFRS compared to CRSsNP and controls; CD8 + T cells were the most

common in CRSwNP and CRSsNP.

IHC of sinonasal mucosa More fungal and nonfungal IgE is expressed in sinonasal mucosa of AFRS patients,

compared with control and CRSsNP patients. There is no significant

correlated with bone erosion.

Dendritic cells and associated chemokines are significantly increased in the mucosa of AFRS and CRSwNP.

difference between AFRS and other forms of EMCRS with respect to percentage of cell populations and

fungal-specific lymphocyte proliferations.

Fungal-specific lymphocyte proliferation was greater in

AFRS/EMCRS regardless of allergy.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Laury 1722 2014 4 Prospective case control study AFRS CRSsNP

Periostin was significantly

Histopathologic and IHC of sinonasal mucosa

Semiquantitative rtPCR and

immunofluorescence of sinus tissue

IHC of mucosa from the OMC

IHC & flow cytometry of polyp, non-polyp tissue and peripheral blood

Clinical characteristics

AFRS-like (fungal allergy, but no fungi in EM)

Nonallergic fungal eosinophilic RS 5. Nonallergic nonfungal

eosinophilic RS

Control group AFRS

Mycetoma

CRSwNP

CRSsNP

Control group CRSsNP AFRS

Control group CRS

CRSwNP

CRSsNP AFRS

AFRS

Ragab 1723 2013 4 Prospective case control study

Ahn 1725 2009 4 Prospective case control study

Ayers 1724 2011 4 Prospective case control study

Pant 1726 2009 4 Prospective case control study

TABLE X-30 (Continued)